China approves Danish drug Wegovy for fatty liver treatment
Chinese health authorities have approved Novo Nordisk's Wegovy for non-alcoholic fatty liver disease.
2026年9月10日
/ DANGDI / DANGDI / DANGDI /Chinese health authorities have approved Novo Nordisk's drug Wegovy for fatty liver treatment. The approval applies to liver disease not caused by alcohol.
The condition is commonly abbreviated as MASH. Danish pharmaceutical company Novo Nordisk announced the approval in a press release reported by Reuters.
Documented liver benefits support Wegovy in managing severe obesity and related diseases. Canada already uses Wegovy to treat this specific liver condition.
Source: DR Nyheder
